Myelofibrosis, polycythemia vera, acute and chronic graft-versus-host-disease. research hub

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ruxolitinib Tablets, 20 mg, manufactured by Sun Pharmaceutical Industries Limited, India with JAKAVI (ruxolitinib) tablets 20 mg, (each Jakavi 20 mg tablet contains 26.40 mg of ruxolitinib phosphate equivalent to 20 mg of ruxolitinib). Imported by: Novartis Biociências SA Av. Prof. Vicente Rao, 90 - São Paulo - SP CNPJ: 56.994.502/0001-30. Manufactured by: Novartis Pharma Stein AG, Stein – Switzerland, in healthy adult, human subjects under fasting condition.

This study compares a new 20mg ruxolitinib tablet from Sun Pharma with the existing Jakavi 20mg tablet. It's for healthy adults to see if the new tablet works the same way in the body when taken on an empty stomach. This helps ensure new medicines are just as effective.